Guanidinoacetate methyltransferase deficiency

Last updated
Guanidinoacetate methyltransferase deficiency
Other namesGAMT deficiency
Creatine neutral.png
Specialty Medical genetics
CausesDeficiency of guanidinoacetate methyltransferase enzyme
Diagnostic method Genetic testing, magnetic resonance spectroscopy, blood and urine testing
TreatmentDietary adjustment and creatine supplementation

Guanidinoacetate methyltransferase deficiency (GAMT deficiency) is an autosomal recessive [1] cerebral creatine deficiency that primarily affects the nervous system and muscles. It is the first described disorder of creatine metabolism, [2] and results from deficient activity of guanidinoacetate methyltransferase, an enzyme involved in the synthesis of creatine. [3] Clinically, affected individuals most commonly present with developmental delay, behavior disorder, and seizures. [4] Diagnosis can be suspected on clinical findings, and confirmed by specific biochemical tests, brain magnetic resonance spectroscopy, or genetic testing. [5] Biallelic pathogenic variants in the GAMT gene are the underlying cause of the disorder. After GAMT deficiency is diagnosed, it can be treated by dietary adjustments, including supplementation with creatine. [6] [7] Treatment is highly effective if started early in life. [8] If treatment is started late, it cannot reverse brain damage which has already taken place. [8] The prevalence of GAMT deficiency is estimated to be 1:250,000. [9]

Contents

Signs and symptoms

Individuals with GAMT deficiency appear normal at birth. Shortly after birth, infants may start to show signs, as the consequences of decreased creatine levels in their body become more apparent. [4] Symptoms generally begin during early infancy (3-6 months) to age two years. [4] These clinical findings are relatively non-specific and do not immediately suggest a disorder of creatine metabolism. The most consistent clinical manifestation is developmental delay or intellectual disability, which is observed in all affected individuals, and can range from mild to severe. [4] Most individuals have severe developmental delay or intellectual disability (50-75%). [4] The next most consistent symptom is a behavior disorder, such as hyperactivity, autism, or self-injurious behavior, reported in 75% of GAMT deficient individuals. [4] The third most consistent symptom is seizures, reported in more than 70% of affected individuals. [4] Additional symptoms include movement disorders, such as chorea, athetosis, dystonia or ataxia, observed in about 30% of GAMT patients. [4]

Depiction showing normal creatine production (top) and disrupted creatine production in GAMT deficiency (bottom) Disrupted creatine production in GAMT deficiency.jpg
Depiction showing normal creatine production (top) and disrupted creatine production in GAMT deficiency (bottom)

Genetics

GAMT (EC 2.1.1.2) catalyzes the second step in the creatine biosynthetic pathway. CreatineSynthesis(en).png
GAMT (EC 2.1.1.2) catalyzes the second step in the creatine biosynthetic pathway.

Biallelic pathogenic variants in GAMT are associated with guanidinoacetate methyltransferase deficiency. Over 70 variants have been reported in the GAMT gene. [10] This gene codes for the enzyme guanidinoacetate methyltransferase (GAMT), which participates in the two-step synthesis of the compound creatine from amino acids glycine, arginine and methionine. Specifically, GAMT controls the second step of the sequence, in which creatine is produced from another compound called guanidinoacetate. [11] GAA is toxic, [12] and because GAMT patients lack the enzyme used to convert GAA to creatine, a build-up of GAA occurs in the brain and other tissues. This accumulation of GAA is thought to cause the more severe symptoms of GATM deficiency. [8] The effects of GAMT deficiency are most severe in organs and tissues that require large amounts of energy, such as the brain and muscles. [8]

This disorder is inherited in an autosomal recessive manner, which means the causative gene is located on an autosome, and two defective copies of the gene – one from each parent – are required to inherit the disorder. The parents both carry one pathogenic variant; however, they are not affected by the disorder. As carriers, the residual activity of approximately 50% is enough to avoid clinical complications. [13] Any siblings of an GAMT deficient individual have a 25% chance of also being GAMT deficient, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. [4]

Diagnosis

GAMT deficiency can be suspected from clinical findings, although clinical findings are not suggestive of a specific diagnosis. The initial diagnosis is typically established via measurement of creatine, creatinine, and guanidinoacetate in plasma, cerebrospinal fluid, or dried blood spots. [5] These measurements can distinguish among the different cerebral creatine deficiency disorders. In GAMT deficiency, laboratory testing of plasma will show decreased levels of creatine and increased levels of guanidinoacetate. [5] A definitive diagnosis requires DNA sequencing of the GAMT gene and/or GAMT enzymatic activity assays. [5] Brain magnetic resonance spectroscopy can also be used in diagnosis, and will show decreased levels of creatine in affected individuals. [5] However, as this finding is seen in all three cerebral creatine deficiencies, further testing is needed to identify the specific defect. [5]

Treatment is most effective for GAMT deficiency with early diagnosis; however, the non-specific clinical findings mean a diagnosis is often delayed. Due to the efficacy of early treatment and the lengthy typical diagnostic journey, GAMT deficiency has been recommended for newborn screening by the United States Advisory Committee on Heritable Disorders in Newborns and Children. [5] Newborn screening assays measure the amount of guanidinoacetate in a dried blood spot using tandem mass spectrometry. Abnormal results from a newborn screening test still need to be confirmed by testing in plasma or urine. [14]

In the United States, Utah started screening for GAMT deficiency in all newborns in 2015. New York started screening newborns in late 2018. [15] In 2020, a GAMT-positive infant was identified via newborn screening in Utah, [16] thus providing evidence that a case could be identified from newborn screening. A second infant was identified in New York in 2021. [16] In 2022, a federal advisory committee voted to include GAMT in the Recommended Universal Screening Panel starting in January 2023. [17] In addition to New York and Utah, California, [18] Pennsylvania, [19] Connecticut, [20] Delaware, [20] and Michigan [20] all currently screen for GAMT.

Around the world, the state of Victoria, Australia began screening for GAMT in 2004, [17] leading to the diagnosis of a newborn at birth in 2022. [21] In Canada, the provinces of Ontario [22] and British Columbia [23] screen for GAMT.

Treatment

Treatment of GAMT deficiency focuses on restoration of depleted brain creatine with oral creatine supplementation in pharmacologic doses, and removal of toxic intermediate GAA via ornithine supplementation and arginine- or protein-restricted diet. [24] [8] Sodium benzoate supplementation is also sometimes used to decrease GAA levels. [7] All patients are reported to benefit from creatine supplementation, with possible improvements or stabilization in symptoms. [6] Seizures appear to reduce more with dietary arginine restriction and ornithine supplementation. [7] Despite treatment, none of the patients have been reported to return to completely normal developmental level, if significant damage had taken place before treatment. [8] Prior to the addition of GAMT deficiency to newborn screening panels, younger siblings of affected individuals may have been tested at birth and treated early. [24] This early treatment can result in outcomes that are very close to normal. [25]

Related Research Articles

<span class="mw-page-title-main">Phenylketonuria</span> Amino acid metabolic disorder

Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders. It may also result in a musty smell and lighter skin. A baby born to a mother who has poorly treated PKU may have heart problems, a small head, and low birth weight.

<span class="mw-page-title-main">Galactosemia</span> Medical condition

Galactosemia is a rare genetic metabolic disorder that affects an individual's ability to metabolize the sugar galactose properly. Galactosemia follows an autosomal recessive mode of inheritance that confers a deficiency in an enzyme responsible for adequate galactose degradation.

<span class="mw-page-title-main">Methylmalonic acidemias</span> Medical condition

Methylmalonic acidemias, also called methylmalonic acidurias, are a group of inherited metabolic disorders, that prevent the body from properly breaking down proteins and fats. This leads to a buildup of a toxic level of methylmalonic acid in body liquids and tissues. Due to the disturbed branched-chain amino acids (BCAA) metabolism, they are among the classical organic acidemias.

<span class="mw-page-title-main">Medium-chain acyl-coenzyme A dehydrogenase deficiency</span> Medical condition

Medium-chain acyl-CoA dehydrogenase deficiency is a disorder of fatty acid oxidation that impairs the body's ability to break down medium-chain fatty acids into acetyl-CoA. The disorder is characterized by hypoglycemia and sudden death without timely intervention, most often brought on by periods of fasting or vomiting.

<span class="mw-page-title-main">Sanfilippo syndrome</span> Rare metabolism disorder

Sanfilippo syndrome, also known as mucopolysaccharidosis type III (MPS III), is a rare lifelong genetic disease that mainly affects the brain and spinal cord. It is caused by a problem with how the body breaks down certain large sugar molecules called glycosaminoglycans (also known as GAGs or mucopolysaccharides). In children with this condition, these sugar molecules build up in the body and eventually lead to damage of the central nervous system and other organ systems.

<span class="mw-page-title-main">Lesch–Nyhan syndrome</span> Rare genetic disorder

Lesch–Nyhan syndrome (LNS) is a rare inherited disorder caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This deficiency occurs due to mutations in the HPRT1 gene located on the X chromosome. LNS affects about 1 in 380,000 live births. The disorder was first recognized and clinically characterized by American medical student Michael Lesch and his mentor, pediatrician William Nyhan, at Johns Hopkins.

Inborn errors of metabolism form a large class of genetic diseases involving congenital disorders of enzyme activities. The majority are due to defects of single genes that code for enzymes that facilitate conversion of various substances (substrates) into others (products). In most of the disorders, problems arise due to accumulation of substances which are toxic or interfere with normal function, or due to the effects of reduced ability to synthesize essential compounds. Inborn errors of metabolism are often referred to as congenital metabolic diseases or inherited metabolic disorders. Another term used to describe these disorders is "enzymopathies". This term was created following the study of biodynamic enzymology, a science based on the study of the enzymes and their products. Finally, inborn errors of metabolism were studied for the first time by British physician Archibald Garrod (1857–1936), in 1908. He is known for work that prefigured the "one gene–one enzyme" hypothesis, based on his studies on the nature and inheritance of alkaptonuria. His seminal text, Inborn Errors of Metabolism, was published in 1923.

<span class="mw-page-title-main">Krabbe disease</span> Medical condition

Krabbe disease (KD) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessive pattern. The disease is named after the Danish neurologist Knud Krabbe (1885–1961).

<span class="mw-page-title-main">Isovaleric acidemia</span> Medical condition disrupting normal metabolism

Isovaleric acidemia is a rare autosomal recessive metabolic disorder which disrupts or prevents normal metabolism of the branched-chain amino acid leucine. It is a classical type of organic acidemia.

<span class="mw-page-title-main">Maple syrup urine disease</span> Autosomal recessive metabolic disorder

Maple syrup urine disease (MSUD) is a rare, inherited metabolic disorder that affects the body's ability to metabolize amino acids due to a deficiency in the activity of the branched-chain alpha-ketoacid dehydrogenase (BCKAD) complex. It particularly affects the metabolism of amino acids—leucine, isoleucine, and valine. With MSUD, the body is not able to properly break down these amino acids, therefore leading to the amino acids to build up in urine and become toxic. The condition gets its name from the distinctive sweet odor of affected infants' urine and earwax due to the buildup of these amino acids.

<span class="mw-page-title-main">Metabolic disorder</span> Any disease hindering the bodys ability to process and distribute nutrients

A metabolic disorder is a disorder that negatively alters the body's processing and distribution of macronutrients, such as proteins, fats, and carbohydrates. Metabolic disorders can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive.

<span class="mw-page-title-main">Short-chain acyl-coenzyme A dehydrogenase deficiency</span> Medical condition

Short-chain acyl-coenzyme A dehydrogenase deficiency (SCADD) is an autosomal recessive fatty acid oxidation disorder which affects enzymes required to break down a certain group of fats called short chain fatty acids.

<span class="mw-page-title-main">3-Methylcrotonyl-CoA carboxylase deficiency</span> Medical condition

3-Methylcrotonyl-CoA carboxylase deficiency also known as 3-Methylcrotonylglycinuria is an inborn error of leucine metabolism and is inherited through an autosomal recessive fashion. 3-Methylcrotonyl-CoA carboxylase deficiency is caused by mutations in the MCCC1 gene, formerly known as MMCA, or the MCCC2 gene, formerly known as MCCB. MCCC1 encodes the a-subunits of 3-methylcrotonyl-CoA carboxylase while MCCC2 encodes the b-subunits. The clinical presentation of 3-Methylcrotonyl-CoA carboxylase deficiency is varied, even within members of the same family.

2-Methylbutyryl-CoA dehydrogenase deficiency is an autosomal recessive metabolic disorder. It causes the body to be unable to process the amino acid isoleucine properly. Initial case reports identified individuals with developmental delay and epilepsy, however most cases identified through newborn screening have been asymptomatic.

<span class="mw-page-title-main">Arginine:glycine amidinotransferase</span> Enzyme

L-Arginine:glycine amidinotransferase is the enzyme that catalyses the transfer of an amidino group from L-arginine to glycine. The products are L-ornithine and glycocyamine, also known as guanidinoacetate, the immediate precursor of creatine. Creatine and its phosphorylated form play a central role in the energy metabolism of muscle and nerve tissues. Creatine is in highest concentrations in the skeletal muscle, heart, spermatozoa and photoreceptor cells. Creatine helps buffer the rapid changes in ADP/ATP ratio in muscle and nerve cells during active periods. Creatine is also synthesized in other tissues, such as pancreas, kidneys, and liver, where amidinotransferase is located in the cytoplasm, including the intermembrane space of the mitochondria, of the cells that make up those tissues.

<span class="mw-page-title-main">Cerebral creatine deficiency</span> Medical condition

Cerebral creatine deficiencies (CCDs) are a small group of inherited disorders that result from defects in creatine biosynthesis and transport. Commonly affected tissues include the brain and muscles. There are three distinct CCDs. The most common is creatine transporter defect (CTD), an X-linked disorder caused by pathogenic variants in creatine transporter SLC6A8. The main symptoms of CTD are intellectual disability and developmental delay, and these are caused by a lack of creatine in the brain, due to the defective transporter. There are also two enzymatic defects of creatine biosynthesis, arginine:glycine amidinotransferase deficiency, caused by variants in GATM gene and guanidinoacetate methyltransferase deficiency, caused by variants in GAMT gene. The two single enzyme defects are both inherited in an autosomal recessive manner.

<span class="mw-page-title-main">Guanidinoacetate N-methyltransferase</span> Class of enzymes

Guanidinoacetate N-methyltransferase is an enzyme that catalyzes the chemical reaction and is encoded by gene GAMT located on chromosome 19p13.3.

<span class="mw-page-title-main">Creatine transporter defect</span> Medical condition

Creatine transporter deficiency (CTD) is an inborn error of creatine metabolism in which creatine is not properly transported to the brain and muscles due to defective creatine transporters. CTD is an X-linked disorder caused by mutation in SLC6A8. SLC6A8 is located at Xq28. Hemizygous males with CTD express speech and behavior abnormalities, intellectual disabilities, development delay, seizures, and autistic behavior. Heterozygous females with CTD generally express fewer, less severe symptoms. CTD is one of three different types of cerebral creatine deficiency (CCD). The other two types of CCD are guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency. Clinical presentation of CTD is similar to that of GAMT and AGAT deficiency. CTD was first identified in 2001 with the presence of a hemizygous nonsense change in SLC6A8 in a male patient.

<span class="mw-page-title-main">Cerebral folate deficiency</span> Medical condition

Cerebral folate deficiency is a condition in which concentrations of 5-methyltetrahydrofolate are low in the brain as measured in the cerebral spinal fluid despite being normal in the blood. Symptoms typically appear at about 5 to 24 months of age. Without treatment there may be poor muscle tone, trouble with coordination, trouble talking, and seizures.

<span class="mw-page-title-main">Arginine:glycine amidinotransferase deficiency</span> Medical condition

Arginine:glycine amidinotransferase deficiency or AGAT deficiency is an autosomal recessive cerebral creatine deficiency caused by a deficiency of the enzyme arginine:glycine amidinotransferase. This enzyme deficiency results in decreased creatine synthesis, and is caused by biallelic pathogenic variants in GATM. Individuals with AGAT deficiency are intellectually disabled and have muscle weakness. The symptoms of AGAT deficiency are caused by the lack of creatine in specific tissues, most notably muscle and brain. Oral creatine supplementation can be used to treat AGAT deficiency, with early intervention providing the best results. All creatine deficiencies are rare, and there have been fewer than 20 individuals reported in medical literature with AGAT deficiency. This disorder was first described in 2000.

References

  1. ↑ Schulze, Andreas (2003). "Creatine deficiency syndromes". Molecular and Cellular Biochemistry. 244 (1/2): 143–150. doi:10.1023/A:1022443503883. ISSN   0300-8177. PMID   12701824. S2CID   25056424.
  2. ↑ Stöckler, S.; Holzbach, U.; Hanefeld, F.; Marquardt, I.; Helms, G.; Requart, M.; Hänicke, W.; Frahm, J. (1994). "Creatine deficiency in the brain: a new, treatable inborn error of metabolism". Pediatric Research. 36 (3): 409–413. doi:10.1203/00006450-199409000-00023. ISSN   0031-3998. PMID   7808840.
  3. ↑ Stöckler, S; Isbrandt, D; Hanefeld, F; Schmidt, B; Von Figura, K (1 May 1996). "Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man" (Free full text). American Journal of Human Genetics. 58 (5): 914–22. ISSN   0002-9297. PMC   1914613 . PMID   8651275.
  4. 1 2 3 4 5 6 7 8 9 Mercimek-Andrews, Saadet; Salomons, Gajja S. (2022), Adam, Margaret P.; Feldman, Jerry; Mirzaa, Ghayda M.; Pagon, Roberta A. (eds.), "Creatine Deficiency Disorders", GeneReviews®, Seattle (WA): University of Washington, Seattle, PMID   20301745 , retrieved 2024-08-27
  5. 1 2 3 4 5 6 7 Sharer, J. Daniel; Bodamer, Olaf; Longo, Nicola; Tortorelli, Silvia; Wamelink, Mirjam M. C.; Young, Sarah (2017). "Laboratory diagnosis of creatine deficiency syndromes: a technical standard and guideline of the American College of Medical Genetics and Genomics". Genetics in Medicine: Official Journal of the American College of Medical Genetics. 19 (2): 256–263. doi:10.1038/gim.2016.203. ISSN   1530-0366. PMID   28055022.
  6. 1 2 Stockler-Ipsiroglu, Sylvia; van Karnebeek, Clara; Longo, Nicola; Korenke, G. Christoph; Mercimek-Mahmutoglu, Saadet; Marquart, Iris; Barshop, Bruce; Grolik, Christiane; Schlune, Andrea; Angle, Brad; Araújo, Helena Caldeira; Coskun, Turgay; Diogo, Luisa; Geraghty, Michael; Haliloglu, Goknur (2014-01-01). "Guanidinoacetate methyltransferase (GAMT) deficiency: Outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring". Molecular Genetics and Metabolism. 111 (1): 16–25. doi:10.1016/j.ymgme.2013.10.018. ISSN   1096-7192.
  7. 1 2 3 Khaikin, Yannay; Sidky, Sarah; Abdenur, Jose; Anastasi, Arnaud; Ballhausen, Diana; Buoni, Sabrina; Chan, Alicia; Cheillan, David; Dorison, Nathalie; Goldenberg, Alice; Goldstein, Jennifer; Hofstede, Floris C.; Jacquemont, Marie-Line; Koeberl, Dwight D.; Lion-Francois, Laurence (16 Feb 2018). "Treatment outcome of twenty-two patients with guanidinoacetate methyltransferase deficiency: An international retrospective cohort study". European Journal of Paediatric Neurology: EJPN: Official Journal of the European Paediatric Neurology Society. 22 (3): 369–379. doi:10.1016/j.ejpn.2018.02.007. ISSN   1532-2130. PMID   29506905.
  8. 1 2 3 4 5 6 Hanna-El-Daher, Layane; Braissant, Olivier (2016-08-01). "Creatine synthesis and exchanges between brain cells: What can be learned from human creatine deficiencies and various experimental models?". Amino Acids. 48 (8): 1877–1895. doi:10.1007/s00726-016-2189-0. ISSN   1438-2199. PMID   26861125.
  9. ↑ Mercimek-Mahmutoglu, S.; Pop, A.; Kanhai, W.; Fernandez Ojeda, M.; Holwerda, U.; Smith, D.; Loeber, J. G.; Schielen, P. C. J. I.; Salomons, G. S. (2016-01-01). "A pilot study to estimate incidence of guanidinoacetate methyltransferase deficiency in newborns by direct sequencing of the GAMT gene". Gene. 575 (1): 127–131. doi:10.1016/j.gene.2015.08.045. ISSN   1879-0038. PMID   26319512.
  10. ↑ Goldstein, Jennifer; Thomas-Wilson, Amanda; Groopman, Emily; Aggarwal, Vimla; Bianconi, Simona; Fernandez, Raquel; Hart, Kim; Longo, Nicola; Liang, Nicole; Reich, Daniel; Wallis, Heidi; Weaver, Meredith; Young, Sarah; Mercimek-Andrews, Saadet (May 2024). "ClinGen variant curation expert panel recommendations for classification of variants in GAMT, GATM and SLC6A8 for cerebral creatine deficiency syndromes". Molecular Genetics and Metabolism. 142 (1): 108362. doi:10.1016/j.ymgme.2024.108362. ISSN   1096-7206. PMID   38452609.
  11. ↑ Clark, Joseph F.; Cecil, Kim M. (2014). "Diagnostic methods and recommendations for the cerebral creatine deficiency syndromes". Pediatric Research. 77 (3): 398–405. doi: 10.1038/pr.2014.203 . ISSN   0031-3998. PMID   25521922. S2CID   6720075.
  12. ↑ Meera, Pratap; Uusi-Oukari, Mikko; Wallner, Martin; Lipshutz, Gerald S. (28 Jan 2023). "Guanidinoacetate ( GAA ) is a potent GABA A receptor GABA mimetic: Implications for neurological disease pathology". Journal of Neurochemistry. 165 (3): 445–454. doi:10.1111/jnc.15774. ISSN   0022-3042. PMID   36726215.
  13. ↑ "612736 CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2". Johns Hopkins University. Retrieved 2019-01-05.
  14. ↑ Ombrone D, Giocaliere E, Forni G, Malvagia S, la Marca G (2016). "Expanded newborn screening by mass spectrometry: New tests, future perspectives" (PDF). Mass Spectrom Rev. 35 (1): 71–84. Bibcode:2016MSRv...35...71O. doi:10.1002/mas.21463. hdl: 2158/1010572 . PMID   25952022. S2CID   21933819. Archived from the original (PDF) on 2022-03-29. Retrieved 2019-09-02.
  15. ↑ "Newborn Screening Program". Association for Creatine Deficiencies. Retrieved 2019-05-05.
  16. 1 2 Hart, Kim; Rohrwasser, Andreas; Wallis, Heidi; Golsan, Heather; Shao, Jianyin; Anderson, Taylor; Wang, Xiaoli; Szabo-Fresnais, Nicolas; Morrissey, Mark; Kay, Denise M.; Wojcik, Matthew; Galvin-Parton, Patricia A.; Longo, Nicola; Caggana, Michele; Pasquali, Marzia (2021-09-01). "Prospective identification by neonatal screening of patients with guanidinoacetate methyltransferase deficiency". Molecular Genetics and Metabolism. 134 (1): 60–64. doi:10.1016/j.ymgme.2021.07.012. ISSN   1096-7192. PMID   34389248.
  17. 1 2 Ream, Margie A.; Lam, Wendy K. K.; Grosse, Scott D.; Ojodu, Jelili; Jones, Elizabeth; Prosser, Lisa A.; Rose, Angela M.; Comeau, Anne Marie; Tanksley, Susan; Powell, Cynthia M.; Kemper, Alex R. (2023-08-01). "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening". Pediatrics. 152 (2): e2023062100. doi:10.1542/peds.2023-062100. ISSN   1098-4275. PMC   10527896 . PMID   37465909.
  18. ↑ "NBS Program Disorders Detectable". www.cdph.ca.gov. Retrieved 2024-08-20.
  19. ↑ "Pennsylvania Bulletin". www.pacodeandbulletin.gov. Retrieved 2024-10-17.
  20. 1 2 3 Therrell, Bradford L.; Padilla, Carmencita D.; Borrajo, Gustavo J. C.; Khneisser, Issam; Schielen, Peter C. J. I.; Knight-Madden, Jennifer; Malherbe, Helen L.; Kase, Marika (2024-05-23). "Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)". International Journal of Neonatal Screening. 10 (2): 38. doi: 10.3390/ijns10020038 . ISSN   2409-515X. PMC   11203842 . PMID   38920845.
  21. ↑ "First Baby with GAMT Deficiency Identified through Newborn Screening in Australia". EIN Presswire. June 29, 2023.
  22. ↑ "Guanidinoacetate Methyltransferase (GAMT) Deficiency". Newborn Screening Ontario. Retrieved 2024-10-15.
  23. ↑ "Metabolic Disorders". www.perinatalservicesbc.ca. Retrieved 2024-10-15.
  24. 1 2 Chen, Daphne (2016-11-02). "Utah mom, doctors push to add rare disorder to national newborn screening panel". Deseret News, Utah. Retrieved 2019-02-18.
  25. ↑ Marten, Lara M.; Krätzner, Ralph; Salomons, Gajja S.; Fernandez Ojeda, Matilde; Dechent, Peter; Gärtner, Jutta; Huppke, Peter; Dreha-Kulaczewski, Steffi (2024-03-01). "Long term follow-up in GAMT deficiency – Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data". Molecular Genetics and Metabolism Reports. 38: 101053. doi:10.1016/j.ymgmr.2024.101053. ISSN   2214-4269. PMC   10926185 . PMID   38469086.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.